US: AOLS - Aeolus Pharmaceuticl

半年間の収益性: +200%

プロモーションスケジュール Aeolus Pharmaceuticl


会社について

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology.

さらに詳しく
Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

IPO date 1996-02-01
ISIN US00765G1094
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.aeoluspharma.com
Цена ао 0.0001
1日あたりの価格変動: 0% (0.0003)
週ごとの価格変動: 0% (0.0003)
月ごとの料金変更: +200% (0.0001)
3ヶ月間の価格変動: +200% (0.0001)
半年間の価格変動: +200% (0.0001)
年間の価格変動: +200% (0.0001)
3年間の価格推移: -62.5% (0.0008)
5年間の価格推移: -76.92% (0.0013)
10年間の価格推移: 0% (0.0003)
年初からの価格変動: +50% (0.0002)

過小評価

名前 意味 学年
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
合計: 2.5

効率

名前 意味 学年
ROA, % 0 0
ROE, % 0 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA 0 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % -71.53 0
収益性 Ebitda, % -49.12 0
収益性 EPS, % -67.11 0
合計: 2

スーパーバイザー 役職 支払い 生年
Mr. John L. Mcmanus Chief Executive Officer and President 1964 (61 年)
Mr. Christopher Stanley Vice President of Operations

住所: United States, Mission Viejo, 26361 Crown Valley Parkway - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.aeoluspharma.com